Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

Aim:  The aim of our study was to comparatively evaluate the efficacy and safety of orlistat and sibutramine treatment in obese hypertensive patients, with a specific attention to cardiovascular effects and to side effects because of this treatment.

[1]  Arya M. Sharma,et al.  Paradoxical Effect of Sibutramine on Autonomic Cardiovascular Regulation , 2002, Clinical autonomic research : official journal of the Clinical Autonomic Research Society.

[2]  J. Wechsler,et al.  Medical management of obesity , 2003, Langenbeck's Archives of Surgery.

[3]  Robert L. Mason,et al.  Statistical Principles in Experimental Design , 2003 .

[4]  R. Macwalter,et al.  Orlistat Enhances Warfarin Effect , 2003, The Annals of pharmacotherapy.

[5]  R. Fogari,et al.  Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. , 2003, Clinical therapeutics.

[6]  R. H. Deusinger,et al.  Obesity: overview of prevalence, etiology, and treatment. , 2003, Physical therapy.

[7]  A. Halpern,et al.  Treatment of obesity: an update on anti‐obesity medications , 2003, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[8]  J. Chan,et al.  Weight management and current options in pharmacotherapy: orlistat and sibutramine. , 2003, Clinical therapeutics.

[9]  K. Fujioka,et al.  Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options. , 2002, Obesity Research.

[10]  K. Narkiewicz.  Sibutramine and its cardiovascular profile , 2002, International Journal of Obesity.

[11]  G. Bakris,et al.  Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension , 2002, Journal of hypertension.

[12]  G. Derosa,et al.  Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open-label trial , 2002 .

[13]  T. Pischon,et al.  Recent developments in the treatment of obesity-related hypertension , 2002, Current opinion in nephrology and hypertension.

[14]  J. Zhi,et al.  Pharmacokinetic Evaluation of the Possible Interaction between Selected Concomitant Medications and Orlistat at Steady State in Healthy Subjects , 2002, Journal of clinical pharmacology.

[15]  Arya M. Sharma,et al.  Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension , 2002, Journal of hypertension.

[16]  W. Weiss.  Pharmacotherapy for obesity. , 2002, The New England journal of medicine.

[17]  E. Wooltorton.  Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  N. Guvener,et al.  Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity , 2002, Diabetes, obesity & metabolism.

[19]  N. Cutler,et al.  Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial , 2002, Journal of Human Hypertension.

[20]  K. Fujioka,et al.  Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors , 2002, Journal of Human Hypertension.

[21]  A. Astrup,et al.  Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity , 2001, Public Health Nutrition.

[22]  M Ishii,et al.  [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[23]  A. Mabadeje.  WHO-ISH Guidelines for the management of hypertension: implementation in Africa--the Nigerian experience. , 1999, Clinical and experimental hypertension.

[24]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[25]  G. Bray,et al.  A double-blind randomized placebo-controlled trial of sibutramine. , 1996, Obesity research.

[26]  L. Gallo.  Cardiovascular Disease , 1995, GWUMC Department of Biochemistry Annual Spring Symposia.

[27]  K. Borner,et al.  Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA-II) , 1977 .

[28]  A. Wahlefeld.  Triglycerides Determination after Enzymatic Hydrolysis , 1974 .

[29]  B. J. Winer,et al.  Statistical Principles in Experimental Design, 2nd Edition. , 1973 .

[30]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[31]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.